MBX Biosciences Appoints Karen Basbaum as Chief Business Officer to Drive Strategic Partnerships
核心洞察
MBX Biosciences (搜索) appointed Karen Basbaum (搜索) as Chief Business Officer, bringing over two decades of experience in biotechnology business development and strategic transactions.
Basbaum previously led strategic partnerships worth over $10 billion in potential value at Poseida Therapeutics and played a key role in the company's $1.5 billion sale to Roche.
The appointment comes as MBX advances its peptide therapy pipeline, including canvuparatide preparing for Phase 3 development for chronic hypoparathyroidism (搜索).
MBX Biosciences (搜索), Inc. (Nasdaq: MBX) announced the appointment of Karen Basbaum (搜索), MBA, as Chief Business Officer, marking a strategic move to strengthen the clinical-stage biopharmaceutical company's business development capabilities as it advances its pipeline of precision peptide therapies for endocrine and metabolic disorders (搜索).
Executive Leadership Addition
Basbaum brings more than two decades of leadership experience in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries. Her appointment comes at a critical juncture as MBX prepares to advance its lead candidate canvuparatide (MBX 2109) into Phase 3 development for chronic hypoparathyroidism (搜索).
"Karen is a highly accomplished and strategic leader with a proven track record of sourcing, structuring, and executing high-value partnerships, financings, and mergers and acquisitions that create long-term shareholder value," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences (搜索). "Her experience executing complex, value-creating agreements with major global pharmaceutical companies will be instrumental as we advance our pipeline and pursue strategic opportunities to maximize the impact of our therapies for patients."
Proven Track Record in Strategic Transactions
Prior to joining MBX Biosciences (搜索), Basbaum served as Senior Vice President of Business Development at Poseida Therapeutics, where she was a member of the Executive Committee and led strategic partnerships and corporate transactions totaling more than $10 billion in potential value. She played a key role in the company's sale to Roche for up to $1.5 billion.
Her career includes senior business development leadership roles at DNAtrix, Dauntless Pharmaceuticals, and Elcelyx Therapeutics, where she led partnering strategies, financings, and strategic initiatives. She also served as Director of Business Development at Amylin Pharmaceuticals, contributing to the company's $7 billion acquisition by Bristol Myers Squibb (搜索).
Pipeline Development Focus
"I am thrilled to join MBX Biosciences (搜索) at such an exciting time in the company's evolution," said Basbaum. "MBX has built a compelling pipeline of innovative peptide therapies with the potential to address significant unmet medical needs. I look forward to working with the talented team to forge strategic partnerships, accelerate development, and help bring these important therapies to patients worldwide."
MBX Biosciences (搜索) is advancing a pipeline of novel candidates for endocrine and metabolic disorders (搜索) with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (搜索) preparing for Phase 3 development, an obesity (搜索) portfolio that includes MBX 4291 in Phase 1 development along with multiple discovery and pre-clinical obesity candidates, and imapextide (搜索) (MBX 1416) for the treatment of post-bariatric hypoglycemia (搜索) in Phase 2 development.
Proprietary Platform Technology
The company's drug development efforts are based on its proprietary PEP™ platform for the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders (搜索). This platform approach allows MBX to target multiple conditions within its therapeutic focus areas.
Basbaum's educational background includes an MBA from the University of California, Irvine; an M.S. in Organic Chemistry from Rensselaer Polytechnic Institute; and dual B.S. degrees in Chemistry and Biology (honors) from the University of North Dakota. She began her career in scientific research roles at Celgene and Abbott Laboratories.